Hale & Tempest

Exploring the Structural Changes in the Global Pharmaceutical Marketplace

Dr. Brian W Tempest

www.briantempest.com

MAPE Fund Managers Conference

Mumbai, India 29 September 2010

Hale & Tempest

Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia

and India where he has lived for the last decade.Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also been Regional Director, Far East for Glaxo where he

was responsible for businesses in Japan, China, Korea, and Taiwan.Brian has worked in the Pharmaceutical Industry for the last 39 years and led Healthcare businesses in North America, South America, Europe, Africa, Middle East, Asia and India. He has also led sessions at Investor Meetings across Asia, Europe and USA. He is now an International Advisor to MAPE – India, Religare -India and UNCTAD - Switzerland. In addition he is a member of the SCRIP Global awards panel. Brian speaks at global conferences on the Challenge from India and China and more

information on these presentations can be found on his website www.briantempest.com.Brian has a PhD in Polymer Chemistry from Lancaster University and is a member of the Royal

Society of Medicine, the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman of Hale & Tempest Co Ltd.

Hale & Tempest

Healthcare Pressures Forever (2050)

Hale & Tempest

Futuristic Pharma Vending Machines -currently being test marketed in UK Hospitals & Supermarkets 2010

Hale & Tempest

The R&D Model is failing

Hale & Tempest

Approvals & Reimbursements Source: Pharmatimes UK July-August 2010

Hale & Tempest

EU Surprise Anti Trust Raids 2008/9

1st - GSK, Astra Zeneca, Sanofi Aventis, Pfizer, Wyeth, Teva in January 2008

2nd – Teva , Servier, Kirka in November 2008

3rd – Sanofi Aventis France, Novartis France, Teva France in October 2009

4th – Lundbeck Italy, Teva UK in December 2009

Hale & Tempest

Many Drugs withdrawn this Decade Source: Deutsche bank, FDA

Hale & Tempest

Generic Exposure

Hale & Tempest

Sales Force Job Cuts in Press since 2009 in H1 2010

Hale & TempestSources: 1. IMS Midas, March 20052. Earth Trend Data Tables 2005

82% of the world population accounts for only 12% of the global pharma sales

Region Pharma Sales Population

North America

Europe

Japan

$255 b 47%

$158 b 30%

$59 b 11%

332 5%

725 11%

128 2%

Asia/Africa/Aus

Latam

88%

$41 b 8%

$20 b 4%

18%

4711 73%

558 9%

12% 82%

Worldwide $533 b 100% 6454 100%

Hale & Tempest

Emerging World Share of Pharma Growth source IMS

Hale & Tempest

Emerging World Share of Pharma SalesSource EIU, OECD, WHO, IMS, Roland Berger

Hale & Tempest

Profitability in Branded Generic Markets

Hale & Tempest

Regional Operating Margins - GSK

Hale & Tempest

Big Pharma & the Emerging World source IMS - BRIC, Mexico, Turkey, South Korea

Hale & Tempest

Emerging Markets & Big Pharma

Hale & Tempest

Big Pharma - New World Order is Coming

Hale & Tempest

Patent Expiries 2003-2013 (in 8 Markets)

Hale & Tempest

USA Generics Filings Source: Deutsche bank July 2010

Hale & Tempest

USA - First to File Lawsuits Source RBC Capital Markets January 15 2010

Hale & Tempest

USA - Litigation Success Rates Source RBC Capital Markets January 15 2010

Patent FTF Challenges on rise Success litigation rate at 48% - or 76%

including deals with patent owner 3 courts hold 69% of cases with a 36%

success rate e.g. NJ 4 courts never ruled against generics e.g. NY At risk launches on the rise – 6 in 2009 Teva has 12 of the 28 at risk launches – 2002/9 Settlements on the rise – 54 in 2009

Hale & Tempest

USA Challenge – Size of Product Basket Source: Deutsche Bank

Hale & Tempest

EU Chain forms a China Generic Factory

UK Coop a GBP£10b UK company Worlds largest consumer cooperative running food stores, banks, insurance, funeral

homes, travel agents, farms and pharmacies 3rd rank pharmacy chain in UK with 800 stores Owns UK pharmaceutical wholesaler Sants Offers 113 products under “Prospect” brand Tianjin Tasly Sants Chinese JV opens 2010/11 With Investment GBP£20m, 200 staff SAP went live Feb 2010

Hale & Tempest

Generic Profit Margin Profile in descending order source: Deutsche Bank July 2010

Hale & Tempest

Indian Generics have consistently outperformed USA Generics

Hale & Tempest

Indian Deals Roaring Ahead July 2010 Grant Thornton Deal Tracker

Hale & Tempest

Top 22 Generic Companies over $1b Source: Company Reports Generics Bulletin 28 May 2010 (excludes Apotex & Actavis Private Companies)

Hale & Tempest

Next18 Generic Companies < $1b Source: Company Reports Generics Bulletin 28 May 2010 (excludes Recalcine Private Company)

Hale & Tempest

The Tempest Crystal Ball

•Asia is becoming the Centre of Gravity for global business

•Big Pharma will develop Emerging World Strategies, Generics Strategies, OTC Strategies, Vaccine Strategies, VC Strategies

•Big Pharma will continue to be attracted to India for CT, EDC, MO. and to China for RM/Biology/Toxicology

•Big Pharma will develop dual IP as well as dual pricing

•In Commodity Generics risks and competition will rise further. Branded Generics will continue to be very attractive

•Many Indian families are reviewing their family portfolios. M&A will roar ahead

•Oncology Monoclonals could be the next wave after HIV

Hale & Tempest

Thank Youbrian.tempest@clara.co.uk

www.briantempest.com